Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

Figure 4

Survival among systemically untreated patients in Stockholm 3 in relation to p4EBP1_S65 and 4EBP1 protein. Kaplan–Meier curves and multivariate Cox regression of distant recurrence-free survival (DRFS) and breast cancer survival (BCS) among systemically untreated patients in the Stockholm 3 cohort in relation to (a) p4EBP1_S65 cytoplasmic protein, (b) p4EBP1_S65 nuclear protein, (c) 4E-binding protein 1 (4EBP1) nuclear protein, (d) 4EBP1 nuclear protein in the progesterone receptor (PgR)-positive subgroup, (e) 4EBP1 protein cytoplasm ≥ nucleus, and (f) 4EBP1 protein cytoplasm ≥ nucleus in the PgR-positive subgroup. The Cox analysis included the following variables: adjuvant tamoxifen treatment, tumour size, Nottingham histological grade, oestrogen receptor alpha, and human epidermal growth factor receptor 2 (HER2) status. *For the PgR-positive/BCS multivariate analyses, HER2 was divided into four groups due to few events. CI, confidence interval; HR, hazard ratio.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us